Tubuloglomerular Feedback in Renal Glucosuria: Mimicking Long-term SGLT-2 Inhibitor Therapy

Zelniker, 2019, SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials, Lancet, 393, 31, 10.1016/S0140-6736(18)32590-X Mann, 2017, Liraglutide and renal outcomes in type 2 diabetes, N Engl J Med, 377, 839, 10.1056/NEJMoa1616011 Thomson, 2012, Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat, Am J Physiol Regul Integr Comp Physiol, 302, R75, 10.1152/ajpregu.00357.2011 Stevens, 2009, Measured GFR as a confirmatory test for estimated GFR, J Am Soc Nephrol, 20, 2305, 10.1681/ASN.2009020171 Lee, 2006, Determination of iohexol clearance by high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS), J Chromatogr B Analyt Technol Biomed Life Sci, 839, 124, 10.1016/j.jchromb.2006.03.057 Mayer, 2019, Analysis from the EMPA-REG OUTCOME((R)) trial indicates empagliflozin may assist in preventing the progression of chronic kidney disease in patients with type 2 diabetes irrespective of medications that alter intrarenal hemodynamics, Kidney Int, 96, 489, 10.1016/j.kint.2019.02.033 Waikar, 2018, Biological variability of estimated GFR and albuminuria in CKD, Am J Kidney Dis, 72, 538, 10.1053/j.ajkd.2018.04.023 Tsampalieros, 2011, Intraindividual variability of the modified Schwartz and novel CKiD GFR equations in pediatric renal transplant patients, Pediatr Transplant, 15, 760, 10.1111/j.1399-3046.2011.01568.x Andreasen, 1984, The influence of age on renal and extrarenal effects of frusemide, Br J Clin Pharmacol, 18, 65, 10.1111/j.1365-2125.1984.tb05023.x